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THE METABOLIC SYNDROME is a common condition comprised of metabolic abnormalities including abdominal obesity, dyslipidemia, hyperglycemia, and hypertension that is associated with an increased risk of type 2 diabetes mellitus (T2DM), cardiovascular diseases (CVD), and atherosclerosis (1, 27, 28) . Diabetes and CVD, the leading cause of death and disability in the Western world, are late end points, and by the time they are established, many systems have already been affected by pathological processes. The prevention of these diseases requires improved understanding of the pathophysiology of the prediabetic and precardiovascular disease state, the metabolic syndrome, and how it contributes to disease development. Numerous mouse models have been generated to study lipid metabolism, atherosclerosis, and diabetes (23, 41) , but to date, fully comprehensive animal models that encompass the multiple features of the metabolic syndrome, including the development of hypertension, remain limited.
The enzyme aromatase is the single gene product of CYP19 and catalyzes the conversion of the C19 androgens to the C18 estrogens (32) . Previous studies have shown that individuals homozygous for a genetic disruption in the CYP19 gene have aromatase deficiency and exhibit a number of clinical features of the metabolic syndrome, notably insulin resistance and high cholesterol. Increased cardiovascular risk and development of diabetes have been reported in aromatase-deficient men and mice (reviewed in Refs. 19 and 37) . Aromatase knockout (ArKO) mice also exhibit central obesity, insulin resistance, elevated cholesterol and triglyceride levels, elevated fasting glucose, and hepatic steatosis (11, 20) . However, this knockout mouse model does not develop atherosclerosis or hypertension.
Apolipoprotein E (ApoE) is a multifunctional protein that is a critical component of triglyceride-rich lipoproteins and highdensity lipoproteins (HDLs), with an essential role in the hepatic metabolism of cholesterol and triglycerides. Genetic variation in the ApoE gene has been shown to be associated with altered plasma lipid concentration (7, 22, 30) , and ApoEdeficient (ApoE Ϫ/Ϫ ) mice exhibit a classic atherogenic phenotype of elevated plasma triglycerides coupled with decreased HDL cholesterol, and increased proinflammatory markers (38) .
In the present study, we sought to create a mouse model that more fully characterizes the metabolic syndrome by crossing ArKO mice, which exhibit central obesity, insulin resistance, elevated cholesterol, and hepatic steatosis (11, 20) , with ApoE Ϫ/Ϫ mice that are prone to atherosclerosis due to dyslipidemia (38) . The development of such a model may provide insight into the mechanistic link between metabolic syndrome, T2DM, and atherosclerotic CVD and facilitate exploration of therapeutic approaches to the prevention and treatment of the metabolic syndrome.
RESEARCH DESIGN AND METHODS
Generation and genotyping of mice. Heterozygous aromatase-deficient (Ar ϩ/Ϫ ) (11) and ApoE Ϫ/Ϫ (38) mice were crossbred to generate dual-heterozygote-deficient progeny (F 1 ). The F 1 progeny were crossbred, and F 2 progeny, which were heterozygous for aromatase deficiency and homozygous for apoE deficiency (Ar ϩ/Ϫ ApoE Ϫ/Ϫ ) were selected as foundation breeders for generating double knockout mice, referred to as MetS-Tg mice. The wild-type (WT) background of each of the lines was C57/BL6. All offspring were genotyped by polymerase chain reaction on genomic DNA extracted from 2 mm of tail tissue collected under anesthesia (halothane) from 4-wkold mice by using a DirectPCR DNA extraction system (Via-gen Biotech, CA). To determine ApoE genotype, the common forward primer (AGAACTGACGTGAGTGTCCA) was used with either a WT reverse primer (GTTCCCAGAAGTT-GAGAAGC) to amplify a 300-bp product in the WT allele or a neomycin cassette-targeting reverse primer (CTTCCTCGT-GCTTTACGGTA) to amplify a 220-bp product from the knockout allele. To determine aromatase genotype, the common forward primer (TGTTATGAATTTTCCAGGAATGG) was used with either a WT reverse primer (GTAAATTCAT-TGGGCTTAGGG) to amplify a 250-bp product in the WT allele or a neomycin cassette-targeting reverse primer (CCA-CAGTCGATGAATCCAGAA) to amplify a 1,000-bp product from the knockout allele.
MetS-Tg and WT mice were followed for 3, 6, and 12 mo. Each genotype and age group consisted of up to 13 males and 8 females. All animals were maintained on standard rodent chow (Meat free Rat and Mouse Diet; Specialty Feeds, Western Australia) with total metabolizable energy of 14.0 MJ/kg for the duration of the study period. Experimental protocols were approved by the Animal Ethics Committee of the University of Otago.
Blood pressure monitoring. Mean arterial blood pressure (MAP) was calculated from systolic and diastolic readings obtained by a noninvasive, computerized tail-cuff system (ADInstruments, Dunedin, New Zealand) as previously described (10) . The mice were familiarized to the procedure by being placed briefly in a restrainer and the tail cuff system over a period of 7 days, after which baseline MAP measurements were made for each animal (mean of Ն10 recordings).
Glucose and insulin tolerance tests. Glucose tolerance tests were performed after a 14-h fast, with 2 g/kg glucose administered via oral gavage (n ϭ 10 mice per group). Peripheral plasma glucose levels were determined from blood samples taken from the tail vein using an automated glucometer (ACCU-CHEK Advantage II; Roche Diagnostics, Mannheim, Germany) prior to oral glucose administration and 15, 30, 60, 90, and 120 min post-glucose gavage. Intraperitoneal insulin tolerance tests were performed on random-fed mice injected with insulin (0.75 U/kg body wt, Actrapid; Novo Nordisk, Auckland, New Zealand), where peripheral plasma glucose levels from blood samples taken from the tail vein were measured before and 15, 30, 45, 60, and 90 min after insulin injection (n ϭ 6 mice per group). The glucose level at the 0-min time point was presented as 100%, and glucose levels recorded at the subsequent time points were calculated as the percentage of the 0-min time point.
Blood biochemistry. Blood was collected by cardiac puncture from animals after euthanaasia, and plasma (n ϭ 9 mice/ group) and serum (n ϭ 6 mice/group) samples were stored at Ϫ80°C until analyzed.
Plasma cholesterol, creatinine, and triglyceride levels were measured by quantitative colorimetric assays (Bioassay Systems) according to the manufacturer's instructions. The detection limits were 0.13 mmol/l (5 mg/dl), 8.8 mol/l (0.01 mg/dl), and 0.01 mmol/l (0.88 mg/dl), respectively. Serum cholesterol, HDL, LDL, and very-low-density (VLDL) lipoprotein levels were measured by a combined quantitative colorimetric assay (Bioassay Systems) according to the manufacturer's instructions, with a detection limit of 0.13 mmol/l (5 mg/dl).
Plasma adiponectin, C-reactive protein (CRP), insulin, interleukin-6 (IL-6), leptin, resistin, and TNF-␣ were measured by multiplexed ELISA (MILLIPLEX Map kit; Millipore) on a Luminex200 (Austin, TX) according to the manufacturer's instructions.
Tissue collection and hepatic and gonadal adipose histology. Following euthanasia, whole liver and gonadal fat pads were separated from connective tissue and wet weights recorded. The left lobe of the liver and regions of the gonadal fat pads were emersion fixed in 10% neutral buffered formalin and then paraffin embedded. Histological analysis was performed on 3-m paraffin sections (Leica Microsystems), stained with hematoxylin and eosin (H&E) and examined under bright-field illumination (Olympus BX50). Five regions of each tissue per animal were photographed with a Leica digital camera (DFC420). Image J public domain software was used to determine adipocyte diameter from ϳ100 measurements across the tissue sections derived from each sample.
Quantitative analysis of atherosclerotic area. For the atherosclerosis study, MetS-Tg and WT mice were compared with an additional control group of age-matched ApoE Ϫ/Ϫ mice (n ϭ 6 mice per age group, equal numbers of both sexes). Whole hearts, with the aortic arch and thoracic aorta attached, were taken and fixed in 10% neutral buffered formalin for at least 24 h. The ventricles were trimmed from the atria and aorta in a plane in line with the tips of the atria. The upper region of the heart was then transferred to formalin containing 10% sucrose overnight at 4°C before being embedded in OCT medium (Miles; Elkhart, IN) and frozen at Ϫ70°C.
To assess aortic lesion location and size, the aortas of all mice were sectioned, and every fifth 8-m section starting from the aortic valve throughout the aortic sinus and down the thoracic branch was collected. Sections were stained using Oil red O, counterstained with Harris' cold hematoxylin, and examined under bright-field illumination (Olympus BX50). The atherosclerotic lesion area was quantified using NIH Image software (Image J 1.4; http://rsb.info.nih.gov/ij) and presented as percentage of total vessel area.
Statistical analysis. All results are expressed as means Ϯ SE. The effects of genotype (MetS-Tg vs. WT), sex, and age were tested by three-way factorial ANOVA. Subsequent comparisons between genotypes at specific ages were performed using independent t-tests. All statistical analyses were performed using SPSS version 16 (SPSS, Chicago, IL). A P value of Ͻ0.05 was considered significant.
RESULTS
Body weight, blood pressure, and heart rate. The body weights of the MetS-Tg mice were significantly greater than age-and sex-matched WT C57Bl/6 mice at each time point measured (3, 6, and 12 mo of age; Table 1 ). MetS-Tg mice had moderately increased MAP compared with WT controls from 3 mo of age (Table 1) , with the degree of hypertension increasing with age at 6 mo and being sustained in older animals. MetS-Tg mice also exhibited a trend for increased heart rate, but this difference was not statistically significant at any age (P ϭ 0.099, 0.070, and 0.820 between genotypes at each age, respectively; Table 1 ). A comparison of males with females within each genotype group showed there was no significant difference in body weight (Table 1 ), blood pressure, or heart rate (data not shown) between sexes for MetS-Tg mice at any age; however, WT male mice were significantly heavier than female mice in all three age groups investigated (P Ͻ 0.002 to P Ͻ 0.008). External examination of MetS-Tg mice suggested a prominent abdominal component to the weight gain observed compared with WT mice.
Serum lipid analysis. Serum cholesterol levels were markedly increased in random-fed, nonfasting, MetS-Tg mice of all ages compared with WT ( Table 2 ). The observed increase in circulating lipids was due to the combined elevation of circulating triglycerides and LDL/VLDL cholesterol particles and was accompanied by a decrease in HDL cholesterol.
Glucose and insulin tolerance testing. After an overnight fast, a small but statistically significant elevation in baseline blood glucose concentration was observed in 3-mo-old MetS-Tg relative to WT mice (Fig. 1A) . Consistent with mild loss of glycemic control, when administered a bolus of glucose, MetS-Tg mice of all ages showed elevated plasma glucose levels ( Fig. 1, A-C) , peaking at 30 min post-glucose administration. The area under the curve of the graph for plasma glucose vs. time was significantly increased in MetS-Tg mice at 6 and 12 mo of age compared with WT controls (Fig. 1, B and C). In response to exogenous insulin administration, at 3 mo of age, MetS-Tg mice displayed a blunted plasma glucose response (Fig. 1A) , which became more pronounced with age compared with WT mice (Fig. 1B and C) .
Plasma biochemistry. Levels of circulating adipokines with known roles in metabolism and inflammation were measured (Table 3) . Adiponectin showed a trend toward increased levels in MetS-Tg mice at 3 and 6 mo of age. MetS-Tg mice of all ages demonstrated trends toward increased CRP, plasma creatinine, IL-6, leptin, and TNF-␣. Of particular interest was the appearance of a proinflammatory state in 12-mo MetS-Tg animals, where plasma levels of CRP, IL-6, and TNF-␣ were all significantly increased compared with WT mice. Plasma resistin levels were largely unchanged between MetS-Tg and WT animals. Plasma leptin concentrations were elevated in MetS-Tg mice of all ages compared with WT mice; however, this difference did not achieve significance (Table 3) . Interestingly, MetS-Tg mice of all ages displayed reduced plasma insulin levels, suggesting impaired insulin secretion in this model.
Body composition and visualization of regional fat mass. MetS-Tg mice of both sexes displayed increased gonadal adipose accumulation compared with WT (Table 4 and Fig. 2 , A and E, respectively). There was no significant difference in the number of individual adipocytes between genotypes at 3- (Fig. 2, B vs. F), 6- (Fig. 2, C vs. G) , or 12 mo of age (Fig. 2,  D vs. H) . However, MetS-Tg mice had greater adipocyte size as demonstrated by a larger mean diameter compared with WT mice (Table 4) . Additionally, the livers of MetS-Tg mice were heavier than those of WT mice at both 3 and 6 mo of age (Table 4) , and from 6 mo of age the livers began to display a yellow coloration compared with WT mice (Fig. 2, I vs. M). Histological analysis identified small lipid droplets forming within livers of MetS-Tg mice at 3 mo of age (Fig. 2N) , becoming more pronounced at both 6 and 12 mo of age (Fig.  2 , O and P) that were not present in livers of aging WT mice (Fig. 2, J-L) .
Atherosclerotic lesion development. We investigated atherosclerotic lesion development in the aortic root and thoracic aorta of MetS-Tg and WT mice and compared lesion size and location to those found in the well-characterized ApoE Ϫ/Ϫ mice. There was no evidence of atherosclerotic lesion formation in WT mice of any age (Fig. 3, A and D) . Small aortic root lesions were detected in both 3-mo-old MetS-Tg and ApoE Ϫ/Ϫ mice (histology images not shown), and despite the seemingly large difference in lesion sizes between genotype groups (Fig. 3G) , the difference was not statistically significant (P ϭ 0.408). Extensive lesions were evident 
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in the aortic root of both MetS-Tg and ApoE Ϫ/Ϫ mice from 6 mo of age (Fig. 3, B and E) , with MetS-Tg mice tending to have slightly larger lesion sizes than the ApoE Ϫ/Ϫ controls ( Fig. 3G , P ϭ 0.085). Again, in 12-mo-old MetS-Tg and ApoE Ϫ/Ϫ mice, large atherosclerotic lesions were evident (Fig. 3, C and F) ; however, no significant difference in lesion area between these groups was detected (Fig. 3G, P ϭ 0.086) . All of the lesions observed were advanced in development and displayed a clear fibrous component to their structure. There was no difference in lesion size between sexes in MetS-Tg mice of any age. Interestingly, however, there was minimal evidence of atherosclerotic plaque formation within the thoracic aorta of MetS-Tg mice; small lesion development was evident in 12-mo-old animals. In comparison, ApoE Ϫ/Ϫ animals displayed thoracic aortic lesions from 6 mo of age (data not shown).
DISCUSSION
The goal of this study was to develop a mouse model that exhibited obesity, hyperlipidemia, insulin resistance, and hy- pertension. Previous mouse models of the metabolic syndrome displayed general obesity and insulin resistance; however, few models have achieved obesity, insulin resistance, and hypertension in a single model without prolonged dietary modification.
ApoE Ϫ/Ϫ mice, with their distinct lipoprotein profile of elevated VLDL cholesterol (38) , are one of the primary models used to investigate hyperlipidemia and atherosclerosis (33, 40) but are generally considered resistant to obesity unless exposed to a high-fat diet (24) . In contrast, ArKO mice display significantly increased adiposity from 10 wk of age (20) . Compared with ArKO mice, MetS-Tg mice do not display as marked an increase in adiposity. However, MetS-Tg mice are significantly heavier than age-and sex-matched WT mice and display increased adipose accumulation throughout the abdomen, suggesting that this novel, double knockout phenotype is one of moderate central obesity as opposed to morbid obesity. In contrast, other mouse models of juvenile onset obesity such as the leptin knockout (ob/ob), leptin receptor-deficient (db/db), or adult onset obesity in the Agouti lethal yellow (A y ) mouse are characterized by more extensive obesity, ranging from 25 to 50% body fat (35) . Additionally, in most cases of metabolic syndrome and obesity-related disorders in humans, the leptin/ leptin receptor axis remains intact and functions normally, unlike in the predominant mouse models of obesity (reviewed in Ref. 23 ). Consistent with the human metabolic syndrome, the MetS-Tg mouse does not demonstrate any significant overexpression of leptin associated with the observed increase in adiposity.
The hyperlipidemia observed in the MetS-Tg mice resembles the lipoprotein profile of the two parental strains, with high total cholesterol as a result of elevations in both the triglyceride and LDL/VLDL fractions in conjunction with a reduction in HDL cholesterol compared with WT. As such, this model is consistent with the human metabolic syndrome characteristic of atherogenic dyslipidemia. Despite the extreme obesity observed in commonly used models, the ob/ob, db/db, and A y mice are resistant to atherosclerotic lesion development, even in the presence of a high-fat diet (35) . Numerous studies suggest that the development of atherosclerosis is an important phenotypic component in any potential animal model of the metabolic syndrome (6, 47) . MetS-Tg mice developed atherosclerotic lesions within the aortic root, which were comparable to those in ApoE Ϫ/Ϫ mice. Given the significant evidence demonstrating the ability of both testosterone and estrogen to impair atherosclerotic lesion development (2, Values are means Ϯ SE; n ϭ 9 mice in each group. 8, 9, 34), it was expected that MetS-Tg mice, with the additional disruption to aromatase function, would display an exacerbated atherosclerotic phenotype compared with ApoE deficiency alone. Instead, it was observed that the rate of atherosclerotic lesion progression was slower in MetS-Tg mice, with smaller plaque sizes evident at 3 mo of age compared with ApoE Ϫ/Ϫ mice. However, this delay in lesion development was no longer evident in older animals. This observed early amelioration in plaque formation suggests an interaction between the two genes. Despite the double knockout construct not producing an aggravated atherosclerotic phenotype, the presence of a persistent and spontaneous atherogenic phenotype within the MetS-Tg mice is critical to achieving a comprehensive model of the metabolic syndrome.
The MetS-Tg mice demonstrated hypertension from a young age compared with WT mice. While the hypertension observed in this mouse model was only moderate, it was evident without dietary modification or exogenous perturbations of major blood pressure-regulating systems such as the renin-angiotensionaldosterone system. While not all individuals with the metabolic syndrome have hypertension, clinical studies have demonstrated that individuals with hypertension as a component of the metabolic syndrome have increased atherosclerosis (13, 18) and that the presence of the metabolic syndrome represents a strong and independent risk factor for future CVD in hypertensive patients (44) . The presence of hypertension as a component of the phenotype of metabolic syndrome mice is critical for comprehensively studying this disorder and is a significant point of difference between this mouse model and other, previously reported models (5, 12, 16, 21, 29, 31, 48) .
Insulin resistance is often considered the cornerstone of the metabolic syndrome and has been consistently linked to the development and exacerbation of atherosclerosis, hypertension, and T2DM (reviewed in Ref. 39) . In humans, central obesity is positively associated with peripheral insulin resistance leading to hyperinsulinemia (4). Similar to humans, elevations in abdominal fat lead to insulin resistance in the commonly studied mouse models of obesity such as the ob/ob and db/db mice. In the current model, glucose intolerance developed in MetS-Tg mice as they aged, becoming frankly abnormal in older transgenic animals. In addition to glucose intolerance, a degree of insulin resistance and impaired insulin secretion was evident in MetS-Tg mice of all ages. Hao et al. (15) recently demonstrated the direct effect of elevated cholesterol on ␤-cell function, where elevated serum cholesterol led to increased cholesterol in the pancreatic islets, directly reducing glucose-stimulated insulin secretion. While MetS-Tg mice demonstrated reduced plasma insulin levels compared with WT mice, this reduction was in conjunction with increased abdominal obesity, ectopic fat accumulation in the liver, increased proinflammatory markers, and a blunted response to exogenous insulin stimulation, suggestive of a lipotoxic environment contributing to ␤-cell dysfunction. The observed progressive impairment in glucose metabolism observed in the MetS-Tg mice is also known to occur in humans with the metabolic syndrome.
Numerous epidemiological studies have documented the association between visceral obesity and cardiovascular risk factors such as dyslipidemia, insulin resistance, and T2DM (3, 26, 46) . Recent attention has been focused on the excessive accumulation of triglycerides within the liver as an additional component of the metabolic syndrome. It appears that fat accumulation within the liver is associated with several features of insulin resistance, even in normal-weight and moderately overweight subjects (25, 45) . Progressive impairment of glucose metabolism is known to occur in humans with the metabolic syndrome, and some studies suggest that insulin resistance further deteriorates as patients progress from fatty liver to nonalcoholic steatosis. MetS-Tg mice developed fat accumulation within the liver as they aged, a further feature of the metabolic syndrome, without the need for dietary modification.
The International Diabetes Federation Consensus Group has highlighted a number of other parameters related to the metabolic syndrome, in particular a proinflammatory state characterized by elevated CRP levels and/or increased inflammatory cytokines such as IL-6 and TNF-␣. Of the markers of inflammation, CRP has been linked to the initiation and progression of atherosclerosis and has been shown in multiple studies to predict incident myocardial infarction, stroke, and sudden cardiac death (42, 43) . The production of proinflammatory cytokines such as Il-6 and TNF-␣ from adipose tissue has also been shown to be predictive of future coronary events (36) . MetS-Tg mice have greater levels of CRP, IL-6, and TNF-␣ than WT controls, suggesting a chronic low-grade inflammatory state indicative of the metabolic syndrome.
In contrast with other mouse models of the metabolic syndrome, the disease phenotype is equally evident in both male and female MetS-Tg mice. The relationship between insulin resistance and hypertension is well established in males, but very few experiments have investigated this association in females. As there are well-documented sex differences regarding the underlying pathological processes leading to both CVD and T2DM (14, 17) , an animal model of the metabolic syn- drome in which both male and females are equally affected is of great scientific value.
In summary, the double knockout, MetS-Tg mouse exhibits a phenotype that includes central obesity, progressive hypertension, an adverse serum lipid profile, atherosclerosis, fatty liver, glucose intolerance, insulin resistance, and evidence of an inflammatory state. These features reflect the characteristics of human metabolic syndrome, and MetS-Tg mice provide a more comprehensive animal model for studying the human disorder.
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